PMID- 17289214
OWN - NLM
STAT- MEDLINE
DCOM- 20070329
LR  - 20151119
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Linking)
VI  - 56
IP  - 4
DP  - 2007 Apr
TI  - New prognostic relevant factors in primary cutaneous diffuse large B-cell 
      lymphomas.
PG  - 588-97
AB  - BACKGROUND: There is a growing body of literature that has enhanced our 
      understanding of the biology of primary cutaneous diffuse large B-cell lymphoma 
      (PCDLBCL) including in the context of gene profiling studies. Recent studies have 
      demonstrated an activated proliferation profile associated with leg type lymphoma 
      including overexpression of proto-oncogenes PIM1, PIM2, and cMYC, and the 
      transcription factors MUM1 and OCT2. Although gene profiling is very useful in 
      understanding the molecular basis of diffuse large B-cell lymphoma (LBCL), it is 
      not practical from a routine diagnostic perspective. In this regard, the purpose 
      of the study was to further define an armamentarium of easily applied 
      immunohistochemical stains to accurately prognosticate PCDLBCL. METHODS: In all, 
      35 patients with PCDLBCL, 14 of follicle center and 21 of leg type, were analyzed 
      using antibodies against CD5, CD138, BCL2, BCL6, OCT2, MUM1, FOXP1, and cMYC. 
      Findings were correlated with clinical data. RESULTS: All cases stained negative 
      for CD5 and CD138. Both subtypes differed in distinct staining patterns for BCL6, 
      BCL2, OCT2, MUM1, and FOXP1. Staining for BCL2, OCT2, and/or MUM1 was associated 
      with poor, and BCL6 with a favorable prognosis. Expression of cMYC was 
      irrespective of prognosis or subtype, whereas ulceration or primary manifestation 
      on the leg or multiple lesions was indicative for worse prognosis. LIMITATIONS: 
      Case number was a limitation. CONCLUSION: Discriminating PCDLBCL supports the 
      validity of the World Health Organization/European Organization for Research and 
      Treatment of Cancer classification. To identify risk factors in patients with 
      PCDLBCL we recommend thorough evaluation of clinical presentation and exploratory 
      staining pattern for BCL2, BCL6, MUM1 and OCT2.
FAU - Hallermann, Christian
AU  - Hallermann C
AD  - Department of Dermatology, Institute for Tumors of the Skin, Munster, Germany. 
      christian.hallermann@fachklinik-hornheide.de
FAU - Niermann, Christoph
AU  - Niermann C
FAU - Fischer, Rudolf-Josef
AU  - Fischer RJ
FAU - Schulze, Hans-Joachim
AU  - Schulze HJ
LA  - eng
PT  - Journal Article
DEP - 20070207
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Organic Cation Transporter 1)
RN  - 0 (Syndecan-1)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/*analysis
MH  - Biopsy, Needle
MH  - Cohort Studies
MH  - Combined Modality Therapy
MH  - Female
MH  - Genes, bcl-2/*genetics
MH  - Humans
MH  - Immunohistochemistry
MH  - Lymphoma, Large B-Cell, Diffuse/mortality/*pathology/therapy
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Organic Cation Transporter 1/genetics/*metabolism
MH  - Probability
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - Risk Factors
MH  - Sampling Studies
MH  - Sensitivity and Specificity
MH  - Sex Factors
MH  - Skin Neoplasms/mortality/*pathology/therapy
MH  - Survival Analysis
MH  - Syndecan-1/genetics/*metabolism
MH  - Tissue Culture Techniques
EDAT- 2007/02/10 09:00
MHDA- 2007/03/30 09:00
CRDT- 2007/02/10 09:00
PHST- 2006/09/13 00:00 [received]
PHST- 2006/11/22 00:00 [revised]
PHST- 2006/12/19 00:00 [accepted]
PHST- 2007/02/10 09:00 [pubmed]
PHST- 2007/03/30 09:00 [medline]
PHST- 2007/02/10 09:00 [entrez]
AID - S0190-9622(07)00018-7 [pii]
AID - 10.1016/j.jaad.2006.12.026 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2007 Apr;56(4):588-97. doi: 10.1016/j.jaad.2006.12.026. Epub 
      2007 Feb 7.